MedTrace Logo

Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion

NCT02674243 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-23

No results posted yet for this study

Summary

This is prospective randomized control trial study. The aim of this study is to evaluate the efficacy of Iodopovidone solution for pleurodesis in palliative malignant pleural effusion (MPE) patients comparing to Talc. All adult patients who diagnosed MPE by cytology regardless primary tumor between December 1, 2015 and November 29, 2016 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand will be enrolled in this study. The inform and consent will be applied in all patients before treatment. Patients will be randomized to two groups; Iodopovidone group (intervention group) and Talc group (control group)

Conditions

  • Malignant Pleural Effusion

Interventions

DRUG

Iodopovidone solution

In this group, iodopovidone solution will be used as pleurodesis substance

DRUG

Talc

In this group, Talc will be used as pleurodesis substance

Sponsors & Collaborators

  • Chiang Mai University

    lead OTHER

Principal Investigators

  • Apichat Tantraworasin · Chiang Mai University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02674243 on ClinicalTrials.gov